 Programmed Cell Death 1 Receptor
"Programmed Cell Death 1 Receptor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitory T-lymphocyte receptor that has specificity for CD274 ANTIGEN and PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN. Signaling by the receptor limits T cell proliferation and INTERFERON GAMMA synthesis. The receptor also may play an essential role in the regulatory pathway that induces PERIPHERAL TOLERANCE.
| Descriptor ID |
D061026
|
| MeSH Number(s) |
D12.776.543.750.705.222.875 D23.050.301.264.894.790 D23.101.100.894.790
|
| Concept/Terms |
Programmed Cell Death 1 Receptor- Programmed Cell Death 1 Receptor
- PD-1 Receptor
- PD 1 Receptor
- Receptor, PD-1
- CD279 Antigen
- Antigen, CD279
- PD1 Receptor
- Receptor, PD1
- Programmed Cell Death 1 Protein
- Antigens, CD279
- CD279 Antigens
|
Below are MeSH descriptors whose meaning is more general than "Programmed Cell Death 1 Receptor".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Costimulatory and Inhibitory T-Cell Receptors [D12.776.543.750.705.222]
- Programmed Cell Death 1 Receptor [D12.776.543.750.705.222.875]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
- Programmed Cell Death 1 Receptor [D23.050.301.264.894.790]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
- Programmed Cell Death 1 Receptor [D23.101.100.894.790]
Below are MeSH descriptors whose meaning is more specific than "Programmed Cell Death 1 Receptor".
This graph shows the total number of publications written about "Programmed Cell Death 1 Receptor" by people in this website by year, and whether "Programmed Cell Death 1 Receptor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 | | 2001 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2007 | 0 | 4 | 4 | | 2008 | 0 | 2 | 2 | | 2009 | 0 | 2 | 2 | | 2010 | 0 | 1 | 1 | | 2011 | 0 | 3 | 3 | | 2012 | 2 | 2 | 4 | | 2013 | 3 | 2 | 5 | | 2014 | 3 | 2 | 5 | | 2015 | 5 | 5 | 10 | | 2016 | 5 | 2 | 7 | | 2017 | 3 | 4 | 7 | | 2018 | 11 | 5 | 16 | | 2019 | 12 | 5 | 17 | | 2020 | 4 | 6 | 10 | | 2021 | 5 | 3 | 8 | | 2022 | 3 | 6 | 9 | | 2023 | 0 | 7 | 7 | | 2024 | 5 | 4 | 9 | | 2025 | 4 | 8 | 12 |
To return to the timeline, click here.
Below are the most recent publications written about "Programmed Cell Death 1 Receptor" by people in Profiles.
-
Narikawa Y, Kuramasu A, Hosonuma M, Murayama M, Funayama E, Sasaki A, Baba Y, Toyoda H, Isobe J, Tajima K, Nakashima R, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Tsurui T, Hirasawa Y, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Horiike A, Kobayashi S, Tsunoda T, Kobayashi S, Kobayashi H, Oguchi T, Shimane T, Kiuchi Y, Yoshimura K. Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity. Cancer Immunol Immunother. 2025 Aug 19; 74(9):289.
-
Nagaoka K, Nakanishi H, Tanaka H, Anindita J, Kawamura T, Tanaka T, Yamashita T, Kuroda A, Nomura S, Akita H, Itaka K, Kodama T, Kakimi K. Neoantigen mRNA vaccines induce progenitor-exhausted T cells that support anti-PD-1 therapy in gastric cancer with peritoneal metastasis. Gastric Cancer. 2025 Sep; 28(5):825-836.
-
Devi KSP, Wang E, Jaiswal A, Konieczny P, Kim TG, Nirschl CJ, Verma A, Liu Y, Milczanowski J, Christo SN, Gandolfo LC, Haitz K, Vardam TD, Wu P, King SL, Tse SW, Pradhan K, Jiang X, Tian T, Fuhlbrigge RC, Schmults CD, Clark RA, Kupper TS, Freeman GJ, Mackay LK, Naik S, Newell EW, Elemento O, Suarez-Farinas M, Anandasabapathy N. PD-1 is requisite for skin TRM cell formation and specification by TGFß. Nat Immunol. 2025 Aug; 26(8):1339-1351.
-
Milhem MM, Wise-Draper TM, Chandra S, Hanna GJ, Laux DE, Medina TM, Ansstas G, Daud A, Kelly CM, O'Day SJ, Perez CA, Wong MK, Friedlander PA, Kristedja TS, Burgess MA, Cowey CL, Hanks BA, Weight RM, Daniel WL, Feltner DE, Mix S, Sindelar L, Bexon AS, Bexon MF, Michel RE, Bhatia S. Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors. J Immunother Cancer. 2025 Jul 25; 13(7).
-
Wilky BA, Julian KA, Maleddu A, Mailhot AC, Cartwright CR, Gao D, Moreno Tellez C, Kemp LE, Therrien NR, Chaudhry SS, Rytlewski JD, Brockman QR, Davila E, Elias AD. A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas. Clin Cancer Res. 2025 Jul 15; 31(14):2945-2956.
-
Muro K, Feinstein T, Baranda J, Bonta I, Yanagitani N, Gersten T, Gandhi L, Kudo T, Fujioka N, Kaplan J, Gorla S, Liu S, Wozniak M, Poondru S, Dillon R, Meng C, Patil T. Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study. Eur J Cancer. 2025 Sep 09; 227:115603.
-
Monson KR, Ferguson R, Handzlik JE, Morales L, Xiong J, Chat V, Dagayev S, Khodadadi-Jamayran A, Simpson D, Kazlow E, Bunis A, Sreenivasaiah C, Ibrahim M, Voloshyna I, Ouwerkerk W, Luiten RM, Capone M, Madonna G, Lu Y, Shao Y, Pavlick A, Krogsgaard M, Mehnert J, Tang H, Dolfi S, Tenney D, Haanen JBAG, Gajewski TF, Hodi FS, Flaherty KT, Couts K, Robinson W, Puzanov I, Ernstoff MS, Rahma O, Postow M, Sullivan RJ, Luke JJ, Ascierto PA, Osman I, Kirchhoff T. Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma. Nat Med. 2025 Jul; 31(7):2385-2396.
-
Day D, Ganju V, Chung K, Si L, Mao L, Aghmesheh M, Hoyer R, Brewin K, Zeng S, Zhang M, Lu Q, Jiang C, Ren F, Zhu Y, Guo J. First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors. Br J Cancer. 2025 Jun; 132(10):905-912.
-
Yokoi M, Murakami K, Yaguchi T, Chamoto K, Ozasa H, Yoshida H, Shirakashi M, Ito K, Komohara Y, Fujiwara Y, Yano H, Ogimoto T, Hira D, Terada T, Hirai T, Tsukamoto H. ICOS+CD4+ T cells define a high susceptibility to anti-PD-1 therapy-induced lung pathogenesis. JCI Insight. 2025 May 22; 10(10).
-
Voorhees TJ, McLaughlin EM, Torka P, Florindez J, Kim NH, Moyo TK, Reves H, Sumransub N, Deshpande S, Rose A, Duarte C, Faisal MS, Hamid S, Subbiah S, Ayyappan S, Shea L, Cortese M, Patel K, Major A, Saeed H, Svoboda J, Desai S, Geethakumari PR, Hamadani M, Grover N, Epperla N. Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers. Blood Cancer J. 2025 03 26; 15(1):45.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|